VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β[1].

Product Specifications

CAS Number

[745833-23-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/VX-702.html

Purity

99.69

Solubility

DMSO : ≥ 42 mg/mL

Smiles

O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O

Molecular Formula

C19H12F4N4O2

Molecular Weight

404.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Kuliopulos A, et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004, 92 (6), 1387-1393.|[2]Braddock M, IDDB Meeting Report, 2005, March 14-15.|[3]Gill A, IDDB Meeing Report, 2002, March 06-08.|[4]Naka K, et al. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun. 2015 Aug 20;6:8039.